Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (184)	12/14/2001 9:39:59 AM
From: tuck	Read Replies (1) of 469

>>OXFORD, UK, Dec. 14 /PRNewswire/ -- Oxford GlycoSciences Plc (LSE: OGS; Nasdaq: OGSI) announced today that Pfizer Inc (NYSE: PFE - news) has extended its research agreement. Pfizer has agreed to extend the research agreement with OGS, which was renewed in December 2000, and provide additional research funding for a further year. OGS will continue to apply its industrial scale proteomics technology to the discovery and utility of biomarkers in the area of atherosclerosis, Alzheimer's disease and certain other undisclosed targets and indications. The programme will also focus on refining the use of the biomarkers. The terms of the December 2000 agreement will continue to apply, under which OGS has the right to commercialise any diagnostic products arising from the collaboration. As part of the extension, Pfizer has renewed its licenses to the OGS human serum and cerebrospinal fluid expression databases and to PC Rosetta(TM), the OGS proprietary data analysis software tool. Michael Kranda, OGS' Chief Executive Officer said, ``We are particularly pleased with the extension of our proteomics agreement with Pfizer. It confirms the positive outcome of our long-term collaboration''.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next